Forsta AP Fonden Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Forsta AP Fonden grew its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 54,800 shares of the biopharmaceutical company’s stock after acquiring an additional 3,900 shares during the period. Forsta AP Fonden’s holdings in Alnylam Pharmaceuticals were worth $12,895,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Huntington National Bank grew its stake in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 45 shares during the last quarter. Hollencrest Capital Management purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $29,000. R Squared Ltd purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $33,000. Washington Trust Advisors Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $42,000. Finally, True Wealth Design LLC grew its stake in shares of Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 153 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on ALNY. Piper Sandler restated an “overweight” rating and issued a $296.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. Bank of America upped their price objective on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research report on Monday, October 14th. StockNews.com cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $298.61.

Alnylam Pharmaceuticals Trading Down 1.9 %

Shares of ALNY stock opened at $273.99 on Thursday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The firm has a market capitalization of $35.34 billion, a PE ratio of -104.58 and a beta of 0.34. The stock has a fifty day simple moving average of $249.42 and a two-hundred day simple moving average of $260.65.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. During the same period in the previous year, the firm earned $1.15 EPS. The business’s quarterly revenue was down 33.3% compared to the same quarter last year. On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.24 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CMO Pushkal Garg sold 52,592 shares of the firm’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. This trade represents a 81.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 73,964 shares of company stock worth $20,622,925. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.